Literature DB >> 4912237

Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Y Hinuma, M Konn, J Yamaguchi, D J Wudarski, J R Blakeslee, J T Grace.   

Abstract

A subline of the P3 (Jijoye) Burkitt lymphoma cell line, designated P3HR-1, initially contained 1 to 5% of cells which were positive by indirect immunofluorescence with selected human sera. After 4 months of propagation, this cell line regularly showed 15 to 40% reactive cells. Antigen(s) in the cell line which was reactive by immunofluorescence was similar or identical to that found in several other Burkitt tumor cell lines in previous studies. When the cells were incubated at 35 or 32 C for 9 to 15 days without refeeding, more than 50% of the cells became immunofluorescence-positive. Thirteen different cultures of P3HR-1 cells, which contained up to 75% immunofluorescence-positive cells, were thin-sectioned and examined by electron microscopy. The percentage of cells containing herpes-type virus particles in the cultures varied from <3 to 78%. There was generally a good correlation between the number of immunofluorescent cells and the number of cells containing virus particles. The number of virus particles per cell section ranged from 1 to more than 100. These results strongly support the hypothesis that the immunofluorescent antigen is related to the presence of the herpes-type virus particle in the cells.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4912237      PMCID: PMC375384     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  BURKITT TUMOR: TISSUE CULTURE, CYTOGENETIC AND VIRUS STUDIES.

Authors:  S E STEWART; E LOVELACE; J J WHANG; V A NGU
Journal:  J Natl Cancer Inst       Date:  1965-02       Impact factor: 13.506

2.  Superiority of fluorescein isothiocyanate (Riggs) for fluorescent-antibody technic with a modification of its application.

Authors:  J D MARSHALL; W C EVELAND; C W SMITH
Journal:  Proc Soc Exp Biol Med       Date:  1958 Aug-Sep

3.  Structure of virus particles extracted from a Burkitt lymphoma cell line.

Authors:  J Yamaguchi; Y Hinuma; J T Grace
Journal:  J Virol       Date:  1967-06       Impact factor: 5.103

4.  Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures.

Authors:  Y Hinuma; J T Grace
Journal:  Proc Soc Exp Biol Med       Date:  1967-01

5.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

6.  Antibody coating and agglutination of virus particles separated from the EB3 line of Burkitt lymphoma cells.

Authors:  W Henle; K Hummeler; G Henle
Journal:  J Bacteriol       Date:  1966-07       Impact factor: 3.490

7.  Indirect immunofluorescence tests with sera from African children and cultured Burkitt lymphoma cells.

Authors:  J A Levy; G Henle
Journal:  J Bacteriol       Date:  1966-07       Impact factor: 3.490

8.  Partial purification and electron microscopy of virus in the EB-3 cell line derived from a Burkitt lymphoma.

Authors:  I Toplin; G Schidlovsky
Journal:  Science       Date:  1966-05-20       Impact factor: 47.728

9.  Studies with Burkitt's lymphoma.

Authors:  M A Epstein; Y M Barr; B G Achong
Journal:  Wistar Inst Symp Monogr       Date:  1965-09

10.  Morphologic, cytogenetic and virologic studies in vitro of a malignant lymphoma from an African child.

Authors:  A S Rabson; G T O'Conor; S Baron; J J Whang; F Y Legallais
Journal:  Int J Cancer       Date:  1966-01       Impact factor: 7.396

View more
  166 in total

1.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Expression of a family of complementary-strand transcripts in Epstein-Barr virus-infected cells.

Authors:  L Karran; Y Gao; P R Smith; B E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

3.  Regulation of the Epstein-Barr virus DNA polymerase gene.

Authors:  F B Furnari; M D Adams; J S Pagano
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

4.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.

Authors:  Amy L Ellis; Zhenxun Wang; Xianming Yu; Janet E Mertz
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

6.  Heterogeneity of Epstein-Barr virus. III. Comparison of a transforming and a nontransforming virus by partial denaturation mapping of their DNAs.

Authors:  H Delius; G W Bornkamm
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

7.  DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus.

Authors:  N Raab-Traub; R Pritchett; E Kieff
Journal:  J Virol       Date:  1978-08       Impact factor: 5.103

8.  Immunological status to Epstein-Barr virus and cytomegalovirus in patients with genital condylomata.

Authors:  M Zerbini; M Musiani; G Gentilomi; S Costa; M G Poggi; M La Placa
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

9.  Iguana virus, a herpes-like virus isolated from cultured cells of a lizard, Iguana iguana.

Authors:  H F Clark; D T Karzon
Journal:  Infect Immun       Date:  1972-04       Impact factor: 3.441

10.  Fast and high-affinity binding of B-lymphotropic papovavirus to human B-lymphoma cell lines.

Authors:  M Herrmann; M Oppenländer; M Pawlita
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.